Here, we identified that sorafenib induced ZFAS1 expression, specifically in sorafenib-resistant HCC cells via the PERK/ATF4-dependent pathway, which is associated with the sorafenib resistance in HCC cells. This evidence concerns the gene ATF4 and hepatocellular carcinoma.